Sanofi to Get Pipeline Boost from Expanded Regeneron Alliance

Bayer Names Christoph Koenen Chief Medical Officer

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

Neurizon Therapeutics Names CEO; Shares Down 4%

Faron Pharmaceuticals Doses First Patient in Phase 1/2 BLAZE Trial of Bexmarilimab Plus Bristol Myers’ Opdivo in PD-1-Resistant Solid Tumors

Sanofi and Regeneron Deepen $8 Billion Immunology Alliance for Next-Gen Antibodies

Enliven Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $75

Merck & Co Inc : Jefferies Raises Target Price to $177 from $175

Liquidia Corporation : Jefferies Cuts Target Price to $45 from $115

Aurora Energy Metals Sets AGM Date and Opens Director Nominations

NH Prime REIT to Outline Business Status at Korea REITs Association Investment Meeting

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

Chimeric Therapeutics Suspended as It Negotiates Creditor Deals and Board Restructure

Lipocine Director John W. Higuchi Acquires 12,561 Common Shares Worth $27,131.76

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind